Predictive value of circulating angiopoietin-2 for endothelial damage-related complications in allogeneic hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 9, 2014, Pages 1335-1340

  Ueda, Norihiro ^a,b   Chihara, Dai ^c   Kohno, Akio ^a   Tatekawa, Shotaro ^a   Ozeki, Kazutaka ^a   Watamoto, Koichi ^a   Morishita, Yoshihisa ^a  

^a Aichi Prefectural Welfare Federation of Agriculture Co operative Associations Konan Kosei Hospital   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Angiopoietin 2; Capillary leak syndrome; Endothelial cell damage; Sinusoidal occlusive syndrome; Transplant associated microangiopathy

Indexed keywords

ANGIOPOIETIN 2;

ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; ALLOTRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOPOIETIN-2; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84905588970     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.04.030     Document Type: Article

References (26)

1. Carreras E., Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 2011, 46:1495-1502.
2. Cooke K.R., Jannin A., Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:23-32.
3. George J.N., Li X., McMinn J.R., et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004, 44:294-304.
4. Cascone T., Heymach J.V. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. JClin Oncol 2012, 30:441-444.
5. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
6. Alves B.E., Montalvao S.A., Aranha F.J., et al. Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia. BMC Infect Dis 2010, 10:143.
7. Kumpers P., David S., Haubitz M., et al. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann Rheum Dis 2009, 68:1638-1643.
8. Luft T., Dietrich S., Falk C., et al. Steroid-refractory GVHD: T-cell attackwithin a vulnerable endothelial system. Blood 2011, 118:1685-1692.
9. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
10. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2009, 15:367-369.
11. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993, 118:255-267.
12. Clark J.G., Hansen J.A., Hertz M.I., et al. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993, 147:1601-1606.
13. Afessa B., Tefferi A., Litzow M.R., et al. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002, 166:641-645.
14. Nurnberger W., Willers R., Burdach S., et al. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol 1997, 74:221-224.
15. Cho B.S., Yahng S.A., Lee S.E., et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010, 90:918-926.
16. Inamoto Y., Ito M., Suzuki R., et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant 2009, 44:43-49.
17. Dignan F.L., Clark A., Amrolia P., et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012, 158:30-45.
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
19. Kishi Y., Kami M., Miyakoshi S., et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation 2005, 80:34-40.
20. Park Y.D., Yoshioka A., Kawa K., et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant 2002, 29:789-794.
21. Cutler C., Kim H.T., Ayanian S., et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant 2010, 16:1180-1185.
22. Scholz A., Lang V., Henschler R., et al. Angiopoietin-2 promotes myeloid cell infiltration in a beta(2)-integrin-dependent manner. Blood 2011, 118:5050-5059.
23. Dietrich S., Falk C.S., Benner A., et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant 2013, 19:22-27.
24. Porkholm M., Bono P., Saarinen-Pihkala U.M., et al. Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT. Bone Marrow Transplant 2013, 48:50-55.
25. Kumpers P., Koenecke C., Hecker H., et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 2008, 112:2139-2148.
26. Loges S., Heil G., Bruweleit M., et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. JClin Oncol 2005, 23:1109-1117.